Page last updated: 2024-08-21

fluorobenzenes and Angiogenesis, Pathologic

fluorobenzenes has been researched along with Angiogenesis, Pathologic in 5 studies

Research

Studies (5)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (40.00)29.6817
2010's3 (60.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Alsayed, A; He, C; Karginova, O; Lee, SS; Olopade, OI; Raoul, A; Weekley, CM; Wu, T1
Chang, CC; Chuang, CL; Hsieh, HG; Huang, HC; Lee, FY; Lee, SD; Lee, WS; Lin, HC; Wang, SS1
Hermonat, PL; Kang, BY; Khaidakov, M; Khan, JA; Mehta, JL; Wang, W1
Bikow, J; Han, R; Keating, A; Lu, B; Parker, TG; Tao, W; Verma, S; Wang, C; Wang, Y; Wen, XY1
Belenkov, IuN; Gabrusenko, SA; Kukharchuk, VV; Masenko, VP; Semenova, AE; Sergienko, IV1

Trials

1 trial(s) available for fluorobenzenes and Angiogenesis, Pathologic

ArticleYear
[Effect of rosuvastatin therapy and myocardial revascularization on angiogenesis in coronary artery disease patients].
    Kardiologiia, 2007, Volume: 47, Issue:11

    Topics: Anticholesteremic Agents; Cholesterol; Female; Fluorobenzenes; Hemodynamics; Humans; Male; Middle Aged; Myocardial Ischemia; Myocardial Revascularization; Neovascularization, Pathologic; Pyrimidines; Receptors, Vascular Endothelial Growth Factor; Rosuvastatin Calcium; Sulfonamides; Transforming Growth Factor beta1; Triglycerides; Vascular Endothelial Growth Factor A

2007

Other Studies

4 other study(ies) available for fluorobenzenes and Angiogenesis, Pathologic

ArticleYear
Inhibition of Copper Transport Induces Apoptosis in Triple-Negative Breast Cancer Cells and Suppresses Tumor Angiogenesis.
    Molecular cancer therapeutics, 2019, Volume: 18, Issue:5

    Topics: Animals; Apoptosis; Benzothiazoles; Bromobenzenes; Cell Line, Tumor; Cell Movement; Cell Proliferation; Copper; Copper Transport Proteins; Copper-Transporting ATPases; Female; Fluorobenzenes; Gene Expression Regulation, Neoplastic; Humans; Mice; Molecular Chaperones; Molybdenum; Neovascularization, Pathologic; Oxidative Stress; Paclitaxel; Small Molecule Libraries; Triple Negative Breast Neoplasms; Tumor Microenvironment; Xenograft Model Antitumor Assays

2019
Rosuvastatin improves hepatopulmonary syndrome through inhibition of inflammatory angiogenesis of lung.
    Clinical science (London, England : 1979), 2015, Volume: 129, Issue:6

    Topics: Administration, Oral; Animals; Disease Models, Animal; Down-Regulation; Fluorobenzenes; Hemodynamics; Hepatopulmonary Syndrome; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Liver; Lung; Male; Neovascularization, Pathologic; Pyrimidines; Rats; Rats, Sprague-Dawley; Reference Values; Rosuvastatin Calcium; Sulfonamides; Tumor Necrosis Factor-alpha; Vascular Endothelial Growth Factor A

2015
Statins and angiogenesis: is it about connections?
    Biochemical and biophysical research communications, 2009, Sep-25, Volume: 387, Issue:3

    Topics: Angiogenesis Inhibitors; Animals; Antigens, CD; Aorta; Cadherins; Cell Adhesion; Cell Movement; Cell Proliferation; Cells, Cultured; Endothelium, Vascular; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Mice; Mice, Inbred C57BL; Neovascularization, Pathologic; Neovascularization, Physiologic; Pyrimidines; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Umbilical Veins

2009
Rosuvastatin, identified from a zebrafish chemical genetic screen for antiangiogenic compounds, suppresses the growth of prostate cancer.
    European urology, 2010, Volume: 58, Issue:3

    Topics: Angiogenesis Inhibitors; Animals; Drug Screening Assays, Antitumor; Fluorobenzenes; Humans; Male; Mice; Mice, SCID; Neovascularization, Pathologic; Prostatic Neoplasms; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; Tumor Cells, Cultured; Zebrafish

2010